683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study
Bunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.Peer-Reviewed Original ResearchRisk of MACEModerate-to-severe diseaseIncidence of MACEMACE riskAdverse cardiovascular eventsAtopic dermatitisMatched controlsRheumatoid arthritisCardiovascular diseaseCardiovascular eventsModerate-to-severe atopic dermatitisAssociated with increased MACE riskRelative risk of MACEMultivariate Cox proportional hazards modelRelative riskCohort entry dateModerate-to-severe ADHistory of cardiovascular diseaseAssociated with multiple comorbiditiesIncreased MACE riskHistory of smokingChronic systemic inflammationFollow-up periodCox proportional hazards modelsUS administrative claims data696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Prajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.Peer-Reviewed Original ResearchSkin symptom severityPatient-reported outcomesAtopic dermatitisSkin painClinically meaningful improvementsUpadacitinib monotherapyPatients treated with upadacitinibPatients randomized to placeboSkin symptomsMeaningful improvementsQuality of lifeTreating moderate-to-severe ADModerate-to-severe ADPhase 3 studyDoses of upadacitinibMinimal clinically important differenceSustained improvementJanus kinase inhibitorsClinically important differenceEvaluate long-term benefitsReduced quality of lifeEczema AreaDLQI 0/1Symptom severityKinase inhibitors697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data
Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of non-melanoma skin cancerModerate-to-severe diseaseAtopic dermatitisNon-AD cohortRheumatoid arthritisControl cohortNon-melanoma skin cancer riskModerate-to-severe atopic dermatitisNon-melanoma skin cancer incidenceMultivariate Cox proportional hazards modelSkin cancerModerate-to-severe ADCohort entry dateSquamous cell carcinomaMatched control cohortIntermittent sun exposureFollow-up timeNon-AD controlsRetrospective observational studyCox proportional hazards modelsEffect of disease activityPopulation-based studyProportional hazards modelClinformatics Data Mart706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.Peer-Reviewed Original ResearchPatient support programAtopic dermatitisItch improvementSkin clearanceOral Janus kinase inhibitorPatient experiencePhase 3 clinical trialsTreating moderate-to-severe ADEffect of upadacitinibMultiple phase 3 clinical trialsModerate-to-severe ADJanus kinase inhibitorsClinical trial resultsPatient-reported experiencesDecreased quality of lifeEvaluate patient experiencePatient-reported outcomesTopical corticosteroidsPatient ageCross-sectional analysisQuality of lifeUpadacitinib dosesKinase inhibitorsUpadacitinibTreatment duration699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study
Mostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.Peer-Reviewed Original ResearchPost-index dateCharlson Comorbidity IndexModerate-to-severe ADMild AAModerate-to-severe AASevere AAModerate-to-severeAlopecia areataAtopic dermatitisMarketScan Commercial ClaimsTopical corticosteroidsAlopecia totalisReal-world prevalenceIndex dateAlopecia universalisHigh-potency topical corticosteroidsMonths post-index dateAA disease severityIncidence of atopic dermatitisHighest prevalencePotency topical corticosteroidsUS administrative claims databasePrevalence of AACox proportional hazards modelsAD comorbidity